RegMed XB

📸 𝗔𝗧𝗠𝗣𝗦𝘄𝗲𝗱𝗲𝗻𝟮𝟬𝟮𝟱 𝗥𝗲𝗰𝗮𝗽 📆 𝟮𝟳–𝟮𝟴 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 Congratulations to the ATMP Sweden team for an inspiring two days in #Gothenburg 🙌 The Nordic community once again showed the strength of collaboration and communication, needed for acceleration, to move effective Advanced Therapy Medicinal Products (ATMPs): medicines based on genes, cells or tissue engineering, to patient solutions. 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 𝗡𝗼𝗿𝗱𝗶𝗰 𝗘𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺 𝗮𝗻𝗱 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 🌍 🚀 Regenerative Medicine in the Netherlands was presented by Bernard Mulder, CEO RegMed XB, outlining how Dutch innovation, industry collaboration, and internationalization strengthen the pathway for ATMP development. 🚀 Jim Lund, CCRM Nordic, opened the session with key insights on Nordic ecosystem coordination and the need for European-level collaboration. 🚀 Christian Gallus, Berlin Institute of Health, shared the progress of Germany’s National Strategy for Gene- and Cell-based Therapies. 🚀 Miguel Salas, Biocat, BioRegion of Catalonia, detailed the growth and global positioning of Catalonia’s life sciences and ATMP landscape. The panel discussion brought these perspectives together, reinforcing the importance of aligned infrastructures, shared expertise, and scalable pathways across Europe. #AdvancedTherapies #LifeSciences #LSH #RegMedXB #Collaboration  #FromCaretoCure

💥 𝙁𝙧𝙤𝙢 𝙨𝙝𝙖𝙧𝙚𝙙 𝙫𝙞𝙨𝙞𝙤𝙣 𝙩𝙤 𝙟𝙤𝙞𝙣𝙩 𝙖𝙘𝙩𝙞𝙤𝙣 💥 As of 2 December, eight initiatives funded by the National Growth Fund/Nationaal Groeifonds are officially joining forces to accelerate Life Sciences & Health innovation and sustainable economic growth, with a focus on societal impact in The Netherlands. 🤝 Biotech Booster, Health-RI, Holomicrobiome Institute, NXTGEN Hightech, Ombion Centre for Animal-free Biomedical Translation, Oncode Accelerator, PharmaNL and RegMed XB signed a Memorandum of Understanding (MoU) to strengthen collaboration across their programs. Read more about this collaboration in the carousel 👇 Or visit the website: https://lnkd.in/eZ5-dsaG Jakob van der Waarden, Conny Helder, Carmen van Vilsteren, Ministry of Economic Affairs, Ministerie van Volksgezondheid, Welzijn en Sport, Ministerie van Financiën, Provincie Utrecht, hollandbio, Netherlands Enterprise Agency (RVO) | Partner in Sustainable Development, Netherlands Enterprise Agency, RVO Health, Health~Holland, Royal Jaarbeurs, Dutch Health Hub, FAST - Centre for Future Affordable Sustainable Therapy Development #LifeScience #HealthInnovation #LifeScienceNews #LSH #MoU 📸 Sherwin Sheybani

Droom je van een mooie regeneratieve oplossing voor patiënten en een push voor je productdevelopment? Dan is dit een mooie kans voor midden- en kleinbedrijf (mkb’ers) en wetenschappelijke instellingen om samen te werken bij onderzoek en ontwikkeling naar een nieuw product of dienst in de regeneratieve geneeskunde! Hard nodig, en nu met beter aansluitende voorwaarden: jonge bedrijven worden nu ook getarget! En een flink budget beschikbaar! Dus, sla de handen in elkaar en go!!!

💸 𝐒𝐮𝐛𝐬𝐢𝐝𝐢𝐞𝐫𝐞𝐠𝐞𝐥𝐢𝐧𝐠 𝐑𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐞𝐟 𝐆𝐞𝐧𝐞𝐞𝐬𝐤𝐮𝐧𝐝𝐢𝐠𝐞 𝐎𝐧𝐝𝐞𝐫𝐳𝐨𝐞𝐤𝐬𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐧 (𝐒𝐑𝐆𝐎) 𝐬𝐮𝐛𝐬𝐢𝐝𝐲 𝐮𝐩𝐝𝐚𝐭𝐞𝐝 𝐚𝐧𝐝 𝐧𝐨𝐰 𝐨𝐩𝐞𝐧! Great news for SMEs and academic partners in regenerative medicine: the updated SRGO scheme has been published and officially reopened. 🗓 Application period: 24 Nov 2025 – 17 Feb 2026 (17:00) 💶 Budget: €10 million – max. €3 million per project 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐧𝐞𝐰 𝐜𝐚𝐥𝐥 • Eased experience requirements for SMEs • New 50–50 loan/grant distribution • More manageable timing of the one-time loan fee • Option to apply under the De Minimis Regulation These updates make the SRGO more accessible and attractive for collaborative innovation in regenerative medicine. 💡 Have a project in mind? Submit a QuickScan to get feedback and support from RVO. 🔗 More information: https://lnkd.in/erUbWfQc Netherlands Enterprise Agency (RVO) | Partner in Sustainable Development, Netherlands Enterprise Agency, RVO Health, Ministerie van Volksgezondheid, Welzijn en Sport, Ministry of Economic Affairs, Ministerie van Financiën, Nationaal Groeifonds, Health~Holland NecstGen, Smart BioMaterials Consortium (SBMC), ReGEN Biomedical, Innovation Center for Advanced Therapies (ICAT), LUMC - Regenerative Medicine, Leiden University Medical Center, Regenerative Medicine Utrecht, MERLN Institute for Technology-Inspired Regenerative Medicine #regenerativemedicine #subsidy #subsidie #SRGO

Looking forward to attending ATMP Sweden this week — excited to connect, learn, and explore new perspectives in the advanced therapies space.

RegMed XB is pleased to invite you to the next Dutch CardioVascular Alliance & RegMed XB Community Event. Mark your calendar: 📅 Date: 12 February 2026 📍Location: Grand Hotel Karel V, Utrecht. More information on the program and registration will be announced soon.

🚀 Cure One launches: an important step forward in the shared mission to cure type 1 diabetes Cure One has officially opened at Leiden University Medical Center, a new research hub where leading scientists are advancing curative therapies for type 1 diabetes. Congratulations to LUMC, LUMC - Regenerative Medicine, DON and the Dutch Diabetes Fund/Diabetes Fonds for achieving this significant milestone 👏 The launch of Cure One aligns closely with the innovation pathway established within the RegMed XB Diabetes Moonshot 🚀 by academic, clinical and industry partners across the Netherlands and Flanders. Technologies now being further developed at Cure One, including stem cell–derived islet cells, biomaterial-based encapsulation systems and immune-protective strategies, originate from collaborative efforts in the RegMed XB ecosystem. Researchers such as Eelco de Koning, Françoise Carlotti, Bahareh Rajaei and Aart van Apeldoorn contribute to both programmes, linking foundational breakthroughs from RegMed XB to translational work within Cure One. This interconnected approach strengthens national and international progress toward durable, accessible and affordable regenerative treatments for type 1 diabetes. Leiden Bio Science Park, Health~Holland, Ministerie van Volksgezondheid, Welzijn en Sport, Ministerie van Financiën, Nationaal Groeifonds, Netherlands Enterprise Agency (RVO) | Partner in Sustainable Development, Netherlands Enterprise Agency, Ministry of Economic Affairs, Gwen Rodenburg, Diena Halbertsma, Rens Vandeberg #RegMedXB #CureOne #DiabetesType1 #RegenerativeMedicine #Biotechnology #Collaboration #Moonshot #Diabetes #FromCareToCure

🔥 What a kick-off! For the new round of the #TTT Program, RegMed XB and Dutch CardioVascular Alliance have teamed up with the Dutch Heart Foundation (Hartstichting), Dutch Brain Foundation (Hersenstichting), Diabetes Fund (Diabetes Fonds), and Dutch Kidney Foundation (Nierstichting). Together, we are building a strong, collaborative program to increase the valorization of research on chronic diseases. Aiming to ultimately create more impact for patients!   Thanks to the Netherlands Enterprise Agency/Netherlands Enterprise Agency (RVO) | Partner in Sustainable Development for awarding this next round of funding for the Thematic Technology Transfer Program. Receiving this grant is a sign of confidence in the foundation we built in the previous round and enables us to further accelerate innovation in the coming years.   💡 Call for innovators: The TTT Program supports promising early-stage projects with the potential to evolve into new medtech or therapeutics start-ups. Through our voucher scheme and follow-on pre-seed investment opportunities, we aim to help teams take the next step toward clinical development. 📍 Are you a researcher at a Dutch academic institution with a technology or idea that could form the basis of a future start-up? We invite you to reach out to us. Let’s explore whether your project could be a fit for a TTT voucher and the support needed to move toward real patient impact! Get in touch with the Impact Officers: Dominique de Jong, Nick Beijer, and Luc Schoppink. Together we make the impossible possible!

FIRST Fund is pleased to share that Margien Boels, PhD, MBA, will speak at the Dutch Life Sciences conference on 20 November at Leiden BioScience Park. She will join the panel for “Biotech Booster: Showcasing Early-stage Projects” at 11:15, where promising Proof-of-Principle innovations from the Biotech Booster program will be presented and discussed with investors and industry experts. The session offers researchers constructive guidance on refining their concepts, evaluating market potential, and preparing for future development and investment. More information can be found in the following link: https://lnkd.in/eQd3wTg8 #events #conference #KOL #lifesciences #biotech